image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 6.81
-0.584 %
$ 277 M
Market Cap
-1.13
P/E
1. INTRINSIC VALUE

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency.[ Read More ]

The intrinsic value of one ANGO stock under the base case scenario is HIDDEN Compared to the current market price of 6.81 USD, AngioDynamics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ANGO

image
FINANCIALS
304 M REVENUE
-10.28%
-97.7 M OPERATING INCOME
-408.07%
-184 M NET INCOME
-251.53%
-28.2 M OPERATING CASH FLOW
-36100.00%
124 M INVESTING CASH FLOW
1369.41%
-64.2 M FINANCING CASH FLOW
-252.75%
67.5 M REVENUE
-4.92%
-13.1 M OPERATING INCOME
-125.63%
-12.8 M NET INCOME
4.84%
-18.3 M OPERATING CASH FLOW
-364.99%
-2.4 M INVESTING CASH FLOW
-2.95%
-509 K FINANCING CASH FLOW
89.82%
Balance Sheet Decomposition AngioDynamics, Inc.
image
Current Assets 193 M
Cash & Short-Term Investments 76.1 M
Receivables 43.6 M
Other Current Assets 73.6 M
Non-Current Assets 124 M
Long-Term Investments 0
PP&E 41.5 M
Other Non-Current Assets 82.9 M
Current Liabilities 91.2 M
Accounts Payable 37.8 M
Short-Term Debt 1.98 M
Other Current Liabilities 51.4 M
Non-Current Liabilities 20.9 M
Long-Term Debt 3.94 M
Other Non-Current Liabilities 17 M
EFFICIENCY
Earnings Waterfall AngioDynamics, Inc.
image
Revenue 304 M
Cost Of Revenue 149 M
Gross Profit 155 M
Operating Expenses 252 M
Operating Income -97.7 M
Other Expenses 86.6 M
Net Income -184 M
RATIOS
50.90% GROSS MARGIN
50.90%
-32.15% OPERATING MARGIN
-32.15%
-60.66% NET MARGIN
-60.66%
-89.67% ROE
-89.67%
-58.03% ROA
-58.03%
-45.72% ROIC
-45.72%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AngioDynamics, Inc.
image
Net Income -184 M
Depreciation & Amortization 27.7 M
Capital Expenditures -5.77 M
Stock-Based Compensation 10.5 M
Change in Working Capital 14.4 M
Others 99.9 M
Free Cash Flow -33.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AngioDynamics, Inc.
image
Wall Street analysts predict an average 1-year price target for ANGO of $12.7 , with forecasts ranging from a low of $12 to a high of $14 .
ANGO Lowest Price Target Wall Street Target
12 USD 76.21%
ANGO Average Price Target Wall Street Target
12.7 USD 86.00%
ANGO Highest Price Target Wall Street Target
14 USD 105.58%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership AngioDynamics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
136 K USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
67 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Oct 10, 2024
Bought 608 USD
Nighan Warren JR
SVP Quality and Regulatory
+ 100
6.08 USD
1 month ago
Oct 07, 2024
Bought 4.68 K USD
Nighan Warren JR
SVP Quality and Regulatory
+ 768
6.09 USD
1 month ago
Oct 08, 2024
Bought 9.96 K USD
Trowbridge Stephen A
EVP and CFO
+ 1700
5.86 USD
1 month ago
Oct 07, 2024
Bought 121 K USD
Clemmer James C
President and CEO
+ 20000
6.03 USD
7 months ago
Apr 08, 2024
Bought 67 K USD
Clemmer James C
President and CEO
+ 10000
6.7 USD
1 year ago
Jan 31, 2023
Sell 60 K USD
Helsel Dave
SVP Global Operations and R&D
- 4633
12.95 USD
2 years ago
Oct 12, 2022
Bought 15 K USD
Trowbridge Stephen A
EVP and CFO
+ 1083
13.82 USD
2 years ago
Oct 10, 2022
Bought 150 K USD
Clemmer James C
President and CEO
+ 10000
15 USD
2 years ago
Jul 29, 2022
Sell 112 K USD
Helsel Dave
SVP Global Operations and R&D
- 5000
22.44 USD
2 years ago
Apr 28, 2022
Sell 78.8 K USD
Helsel Dave
SVP Global Operations and R&D
- 3513
22.44 USD
2 years ago
Apr 11, 2022
Sell 143 K USD
JOHNSON WESLEY
Director
- 6201
23 USD
2 years ago
Apr 11, 2022
Sell 30.2 K USD
JOHNSON WESLEY
director:
- 1299
23.26 USD
2 years ago
Jan 12, 2022
Bought 22.6 K USD
Trowbridge Stephen A
EVP and CFO
+ 1000
22.64 USD
2 years ago
Jan 11, 2022
Bought 228 K USD
Clemmer James C
President and CEO
+ 10000
22.84 USD
3 years ago
Oct 20, 2021
Sell 97.7 K USD
Helsel Dave
SVP Global Operations and R&D
- 3494
27.97 USD
3 years ago
Oct 15, 2021
Sell 335 K USD
Centea Scott
Sr. VP/GM, Global VIT
- 12000
27.92 USD
3 years ago
Oct 05, 2021
Sell 292 K USD
Campbell Chad Thomas
SVP/GM, Vascular Access
- 10748
27.15 USD
3 years ago
Apr 14, 2021
Sell 83.8 K USD
Helsel Dave
SVP Global Operations and R&D
- 3500
23.93 USD
3 years ago
Jan 20, 2021
Sell 120 K USD
JOHNSON WESLEY
Director
- 6500
18.53 USD
4 years ago
Aug 11, 2020
Bought 9.5 K USD
Trowbridge Stephen A
EVP and CFO
+ 1013
9.38 USD
4 years ago
Jul 31, 2020
Bought 330 K USD
Clemmer James C
President and CEO
+ 40000
8.26 USD
5 years ago
Oct 25, 2019
Bought 213 K USD
Clemmer James C
President and CEO
+ 15000
14.19 USD
5 years ago
Jul 16, 2019
Sell 293 K USD
Gould Kevin J
Director
- 13650
21.45 USD
6 years ago
Nov 07, 2018
Sell 41.7 K USD
Greiner Michael
EVP and CFO
- 1939
21.53 USD
7 years ago
Nov 15, 2017
Sell 446 K USD
Richard Stark
SVP, GM - Oncology
- 27409
16.29 USD
7 years ago
Jul 24, 2017
Bought 5.06 K USD
REED JAN STERN
Director
+ 316
16 USD
7 years ago
Jul 21, 2017
Bought 78.6 K USD
DONNELLY HOWARD W
Director
+ 5000
15.72 USD
7 years ago
Jul 21, 2017
Bought 79 K USD
Clemmer James C
President and CEO
+ 5000
15.79 USD
7 years ago
Jul 20, 2017
Bought 313 K USD
Clemmer James C
President and CEO
+ 20000
15.64 USD
7. News
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 2 weeks ago
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next? ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance. zacks.com - 2 weeks ago
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE AngioDynamics announces the receipt of CPT Category I code for IRE technology. zacks.com - 3 weeks ago
AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com - 1 month ago
AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business. zacks.com - 1 month ago
Here's Why You Should Add AngioDynamics Stock to Your Portfolio ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors. zacks.com - 1 month ago
Why AngioDynamics Stock Is Crashing Today Investors didn't like the medical technology company's fiscal 2025 Q1 update. fool.com - 1 month ago
AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday. benzinga.com - 1 month ago
AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates AngioDynamics (ANGO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago. zacks.com - 1 month ago
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights   Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million. businesswire.com - 1 month ago
Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3. benzinga.com - 1 month ago
New Strong Buy Stocks for September 30th MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024. zacks.com - 1 month ago
8. Profile Summary

AngioDynamics, Inc. ANGO

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 277 M
Dividend Yield 0.00%
Description AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Contact 14 Plaza Drive, Latham, NY, 12110 https://www.angiodynamics.com
IPO Date June 1, 2004
Employees 748
Officers Mr. Juan Carlos Serna Senior Vice President of Scientific & Clinical Affairs Mr. Benjamin H. Davis Senior Vice President of Business Development & Strategy Ms. Marna I. Bronfen-Moore Senior Vice President of Human Resources Mr. Chad T. Campbell Senior Vice President and GM of Global Vascular Access & Oncology Business Unit Mr. Warren G. Nighan Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain Ms. Kim L. Seabury Senior Vice President of Information Technology Mr. Stephen A. Trowbridge Executive Vice President & Chief Financial Officer Mr. James C. Clemmer Chief Executive Officer, President & Director Ms. Laura Piccinini Senior Vice President & GM of Endovascular Therapies and International Mr. Saleem M. Cheeks Vice President of Communications